Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Diagnostear Technologies Inc C.DTR

DiagnosTear Technologies Inc., an ophthalmic company, engages in developing and commercializing disruptive diagnostic solutions for eye diseases. It develops TeaRx Dry Eye, a CE-IVD approved test based on the TeaRx platform intended for the identification and monitoring of Dry Eye Syndrome (TeaR DES); TeaRx Red Eye for differential assessment of adenoviral conjunctivitis, herpetic keratitis, and allergic conjunctivitis; and TeaRx Tear Collector, a proprietary microfluidic tear collector that allows non-invasive collection of 1 microliter of tear fluid and dilution in the assay buffer for downstream analytical testing. DiagnosTear Technologies Inc. was formerly known as Oceanview Technologies Inc. and changed its name to DiagnosTear Technologies Inc. The company was incorporated in 2023 and is headquartered in Rehovot, Israel.


CSE:DTR - Post by User

User Avatar Image
(0)
•••
  • Jeremiah243X
Post by Jeremiah243on Dec 20, 2025 4:00pm
35 Views
Post# 36833170

Dry Eye Syndrome

Dry Eye SyndromeDoes anyone on this board know if this company's dry eye syndrome technology is only meant to detect if a patient has the disease or whether they actually provide treatment to cure the disease?
<< Previous
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities